Problems Still Abound For FDA's Accredited Persons Inspection Program
This article was originally published in The Silver Sheet
FDA'S ACCREDITED PERSONS (AP) INSPECTION PROGRAM IS STRUGGLING because of financial costs to manufacturers, difficulties in getting third-party auditors trained and industry apathy, experts say. Since it was created in 2003, only about 90 inspections have been completed under the program, which allows manufacturers to hire agency-approved auditors to conduct FDA quality system inspections. "It would be very helpful if industry really embraced the program, but the bottom line is that industry is not embracing it," David Kalins, CDRH's AP program coordinator says. Two of the 16 auditing firms certified by the agency to perform AP inspections - Underwriters Laboratories and TUV SÜD America - talk about the challenges they face. Meanwhile, an updated FDA guidance on the AP program explains statutory changes made in 2007 that make it easier for firms to take part
You may also be interested in...
The FDA Reauthorization Act, enacted last month, includes provisions that aim to improve FDA's inspection process, including putting a stop to arbitrary audit scheduling by the agency – a practice that can cause a facility inspection to drag on for weeks at a time. FDA has until early 2019 to draft a guidance document that lays out how it will ensure a more uniform inspection process that ensures greater parity between foreign and domestic audits. Steps mandated by the new law include notifying firms in advance of records that will be requested during an inspection and specifying a window of time for investigators to conduct the onsite inspections. But industry experts are of two minds as to whether any substantial changes will result from the new law. Also: FDA device center Director Jeff Shuren weighs in.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.